<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02835625</url>
  </required_header>
  <id_info>
    <org_study_id>247941/H10</org_study_id>
    <nct_id>NCT02835625</nct_id>
  </id_info>
  <brief_title>The Digital Breast Tomosynthesis Trial in Bergen</brief_title>
  <acronym>TOBE</acronym>
  <official_title>Digital Breast Tomosynthesis - The Future Screening Tool for Breast Cancer?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Registry of Norway</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Research Council of Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cancer Registry of Norway</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare synthetic mammography+digital breast tomosynthesis (SM+DBT) with digital mammography&#xD;
      (DM) as a screening tool for women aged 50-69 years, invited to participate in the Norwegian&#xD;
      Breast Cancer Screening Program at the screening unit in Bergen, Norway, with regard to early&#xD;
      performance measures, including prognostic and predictive tumor characteristics, radiation&#xD;
      doses and cost-effectiveness.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DBT is a new screening tool, argued to be better than standard DM. This statement is based on&#xD;
      a lower recall rate, and a higher rate of early-stage screen-detected cancer. No studies have&#xD;
      so far reported results from women screened with DBT from GE Healthcare, as far as the&#xD;
      investigators know. DBT from GE offer synthetic two-dimensional DM generated from the DBT&#xD;
      data (SM), and studies have shown similar detection rates for this technique as of adjacent&#xD;
      DM. By comparing results of early performance measures and economic aspects in two comparable&#xD;
      populations of women in the same age group, residing in the same county, the investigators&#xD;
      can measure the effect of SM+DBT versus standard DM with equipment from GE Healthcare. The&#xD;
      populations will be examined by the same radiographers, screen-read by the same radiologists,&#xD;
      histologically breast cancer proven by the same pathologists, and treated by the same&#xD;
      surgeons and oncologists.&#xD;
&#xD;
      A prospective cohort study targeting 45,000 women invited to breast cancer screening in&#xD;
      Bergen, Hordaland in the study period, 2016-2018, will be performed. A screening&#xD;
      participation of approximately 75% is expected. All attending women will be asked if they are&#xD;
      willing to participate in the study after receiving written and oral information about the&#xD;
      study. Women willing to participate in the study will sign an informed consent. Of the&#xD;
      attending women it is expected that about 90-95% will consent to participate in the study.&#xD;
      The women will be randomized into two groups, a study group and a control group. The&#xD;
      randomization will take place at the screening unit in Bergen. The outcome of the&#xD;
      randomization is based on the 11-digit personal identification number assigned to every&#xD;
      citizen in Norway. In the study group, the women will be screened with SM+DBT. In the control&#xD;
      group, the women will be screened with DM. Women not willing to participate in the study will&#xD;
      be screened with DM, and not included in our study.&#xD;
&#xD;
      The investigators aim to address the following topics and research questions:&#xD;
&#xD;
        -  Study 1: Early performance measures in a population based screening program using SM+DBT&#xD;
           versus DM - interim analyses.&#xD;
&#xD;
        -  Study 2: Use of SM+DBT versus DM in a population based screening program - a randomized&#xD;
           controlled trial.&#xD;
&#xD;
        -  Study 3: Prognostic and predictive histopathologic characteristics of breast tumors&#xD;
           detected in a population based program using SM+DBT versus DM.&#xD;
&#xD;
        -  Study 4: SM+DBT and DM in a populations based screening program - which technology has&#xD;
           the highest sensitivity for women with mammographic dense breast?&#xD;
&#xD;
        -  Study 5 and 6: Costs of SM+DBT and DM in a populations based screening program - is&#xD;
           SM+DBT cost-effective?&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">May 2021</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Screen-Detected Breast Cancer</measure>
    <time_frame>36 months from start up of the trial</time_frame>
    <description>Comparison of rates of screen-detected breast cancer in tomosynthesis versus digital mammography as performed in a population based screening program.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Participants Screen-Detected Breast Cancer Among Participants Recalled for Further Assesment</measure>
    <time_frame>36 months from start up of the trial</time_frame>
    <description>Positive predictive value of recalls (number of screen-detected breast cancer among participants recalled for further assesment) for tomosynthesis versus digital mammography in a population based screening program.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Recalled for Further Assesment Due to Mammographic Findings</measure>
    <time_frame>36 months from start up of the trial</time_frame>
    <description>Comparison of rate of recall for further assesment due to mammographic findings in tomosynthesis versus digital mammography as performed in a population based screening program.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Costs of Screening With Tomosynthesis Versus Digital Mammography</measure>
    <time_frame>36 months from start up of the trial</time_frame>
    <description>The incremental cost per woman screened with digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening program.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic and Predictive Tumor Characteristics for Screen-Detected Breast Cancer</measure>
    <time_frame>36 months from start up of the trial</time_frame>
    <description>Distribution of characteristics among the women diagnosed with breast cancer screened with tomosynthesis versus digital mammography in a population based screening program.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Interval Breast Cancer</measure>
    <time_frame>60 months from start up of the trial</time_frame>
    <description>Rate of interval breast cancer among those screened with tomosynthesis versus digital mammography as performed in a population based screening program.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time Spent on Screen-Reading and Consensus Meetings</measure>
    <time_frame>24 months from start up of the trial</time_frame>
    <description>The time spent on screen-reading and consensus will be compared for tomosynthesis versus digital mammography</description>
  </other_outcome>
  <other_outcome>
    <measure>Mammographic Features of Screen-Detected Breast Cancer</measure>
    <time_frame>36 months from start up of the trial</time_frame>
    <description>Distribution of characteristics among the women diagnosed with breast cancer screened with tomosynthesis versus digital mammography in a population based screening program.</description>
  </other_outcome>
  <other_outcome>
    <measure>Radiation Doses When Screening With Tomosynthesis Versus Digital Mammography</measure>
    <time_frame>24 months from start up of the trial</time_frame>
    <description>Radiation doses will be measured for screening with tomosynthesis and digital mammography by an automated software, in milligray (mGy).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29453</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Digital Breast Tomosynthesis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Synthetic Mammography (SM) + Digital Breast Tomosynthesis (DBT)&#xD;
The SM+DBT will be independently read by two radiologists. A consensus meeting will decide whether to recall the woman or not.&#xD;
Women selected for further assessment (positive screening exam) will be recalled.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Digital mammography</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The digital mammograms will be independently read by two radiologists. A consensus meeting will decide whether to recall the woman or not.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Synthetic Mammography + Digital Breast Tomosynthesis</intervention_name>
    <description>Two-view tomosynthesis performed with GE Senoclaire 3D Breast Tomosynthesis.</description>
    <arm_group_label>Digital Breast Tomosynthesis</arm_group_label>
    <other_name>SM+DBT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Digital mammography</intervention_name>
    <description>Two-view digital mammography performed with GE Senoclaire 3D Breast Tomosynthesis.</description>
    <arm_group_label>Digital mammography</arm_group_label>
    <other_name>DM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Breast implants&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>48 Years</minimum_age>
    <maximum_age>71 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Solveig Hofvind, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Registry of Norway</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <state>Hordaland</state>
        <zip>0521</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Registry of Norway</name>
      <address>
        <city>Oslo</city>
        <zip>0379</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Skaane P, Bandos AI, Gullien R, Eben EB, Ekseth U, Haakenaasen U, Izadi M, Jebsen IN, Jahr G, Krager M, Niklason LT, Hofvind S, Gur D. Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population-based screening program. Radiology. 2013 Apr;267(1):47-56. doi: 10.1148/radiol.12121373. Epub 2013 Jan 7.</citation>
    <PMID>23297332</PMID>
  </reference>
  <reference>
    <citation>Ciatto S, Houssami N, Bernardi D, Caumo F, Pellegrini M, Brunelli S, Tuttobene P, Bricolo P, Fantò C, Valentini M, Montemezzi S, Macaskill P. Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study. Lancet Oncol. 2013 Jun;14(7):583-9. doi: 10.1016/S1470-2045(13)70134-7. Epub 2013 Apr 25.</citation>
    <PMID>23623721</PMID>
  </reference>
  <reference>
    <citation>Lång K, Andersson I, Rosso A, Tingberg A, Timberg P, Zackrisson S. Performance of one-view breast tomosynthesis as a stand-alone breast cancer screening modality: results from the Malmö Breast Tomosynthesis Screening Trial, a population-based study. Eur Radiol. 2016 Jan;26(1):184-90. doi: 10.1007/s00330-015-3803-3. Epub 2015 May 1.</citation>
    <PMID>25929946</PMID>
  </reference>
  <reference>
    <citation>Haas BM, Kalra V, Geisel J, Raghu M, Durand M, Philpotts LE. Comparison of tomosynthesis plus digital mammography and digital mammography alone for breast cancer screening. Radiology. 2013 Dec;269(3):694-700. doi: 10.1148/radiol.13130307. Epub 2013 Oct 28.</citation>
    <PMID>23901124</PMID>
  </reference>
  <reference>
    <citation>Durand MA, Haas BM, Yao X, Geisel JL, Raghu M, Hooley RJ, Horvath LJ, Philpotts LE. Early clinical experience with digital breast tomosynthesis for screening mammography. Radiology. 2015 Jan;274(1):85-92. doi: 10.1148/radiol.14131319. Epub 2014 Sep 1.</citation>
    <PMID>25188431</PMID>
  </reference>
  <reference>
    <citation>Friedewald SM, Rafferty EA, Rose SL, Durand MA, Plecha DM, Greenberg JS, Hayes MK, Copit DS, Carlson KL, Cink TM, Barke LD, Greer LN, Miller DP, Conant EF. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 2014 Jun 25;311(24):2499-507. doi: 10.1001/jama.2014.6095.</citation>
    <PMID>25058084</PMID>
  </reference>
  <reference>
    <citation>Rose SL, Tidwell AL, Bujnoch LJ, Kushwaha AC, Nordmann AS, Sexton R Jr. Implementation of breast tomosynthesis in a routine screening practice: an observational study. AJR Am J Roentgenol. 2013 Jun;200(6):1401-8. doi: 10.2214/AJR.12.9672.</citation>
    <PMID>23701081</PMID>
  </reference>
  <reference>
    <citation>McCarthy AM, Kontos D, Synnestvedt M, Tan KS, Heitjan DF, Schnall M, Conant EF. Screening outcomes following implementation of digital breast tomosynthesis in a general-population screening program. J Natl Cancer Inst. 2014 Oct 13;106(11). pii: dju316. doi: 10.1093/jnci/dju316. Print 2014 Nov.</citation>
    <PMID>25313245</PMID>
  </reference>
  <reference>
    <citation>Greenberg JS, Javitt MC, Katzen J, Michael S, Holland AE. Clinical performance metrics of 3D digital breast tomosynthesis compared with 2D digital mammography for breast cancer screening in community practice. AJR Am J Roentgenol. 2014 Sep;203(3):687-93. doi: 10.2214/AJR.14.12642. Epub 2014 Jun 11.</citation>
    <PMID>24918774</PMID>
  </reference>
  <reference>
    <citation>Lourenco AP, Barry-Brooks M, Baird GL, Tuttle A, Mainiero MB. Changes in recall type and patient treatment following implementation of screening digital breast tomosynthesis. Radiology. 2015 Feb;274(2):337-42. doi: 10.1148/radiol.14140317. Epub 2014 Sep 22.</citation>
    <PMID>25247407</PMID>
  </reference>
  <reference>
    <citation>Destounis S, Arieno A, Morgan R. Initial experience with combination digital breast tomosynthesis plus full field digital mammography or full field digital mammography alone in the screening environment. J Clin Imaging Sci. 2014 Feb 25;4:9. doi: 10.4103/2156-7514.127838. eCollection 2014.</citation>
    <PMID>24744966</PMID>
  </reference>
  <reference>
    <citation>Skaane P, Bandos AI, Eben EB, Jebsen IN, Krager M, Haakenaasen U, Ekseth U, Izadi M, Hofvind S, Gullien R. Two-view digital breast tomosynthesis screening with synthetically reconstructed projection images: comparison with digital breast tomosynthesis with full-field digital mammographic images. Radiology. 2014 Jun;271(3):655-63. doi: 10.1148/radiol.13131391. Epub 2014 Jan 24.</citation>
    <PMID>24484063</PMID>
  </reference>
  <reference>
    <citation>Zuley ML, Guo B, Catullo VJ, Chough DM, Kelly AE, Lu AH, Rathfon GY, Lee Spangler M, Sumkin JH, Wallace LP, Bandos AI. Comparison of two-dimensional synthesized mammograms versus original digital mammograms alone and in combination with tomosynthesis images. Radiology. 2014 Jun;271(3):664-71. doi: 10.1148/radiol.13131530. Epub 2014 Jan 21.</citation>
    <PMID>24475859</PMID>
  </reference>
  <reference>
    <citation>Gilbert FJ, Tucker L, Gillan MG, Willsher P, Cooke J, Duncan KA, Michell MJ, Dobson HM, Lim YY, Suaris T, Astley SM, Morrish O, Young KC, Duffy SW. Accuracy of Digital Breast Tomosynthesis for Depicting Breast Cancer Subgroups in a UK Retrospective Reading Study (TOMMY Trial). Radiology. 2015 Dec;277(3):697-706. doi: 10.1148/radiol.2015142566. Epub 2015 Jul 15.</citation>
    <PMID>26176654</PMID>
  </reference>
  <reference>
    <citation>Houssami N, Skaane P. Overview of the evidence on digital breast tomosynthesis in breast cancer detection. Breast. 2013 Apr;22(2):101-108. doi: 10.1016/j.breast.2013.01.017. Epub 2013 Feb 16. Review.</citation>
    <PMID>23422255</PMID>
  </reference>
  <reference>
    <citation>Bonafede MM, Kalra VB, Miller JD, Fajardo LL. Value analysis of digital breast tomosynthesis for breast cancer screening in a commercially-insured US population. Clinicoecon Outcomes Res. 2015 Jan 12;7:53-63. doi: 10.2147/CEOR.S76167. eCollection 2015.</citation>
    <PMID>25624767</PMID>
  </reference>
  <reference>
    <citation>Lee CI, Cevik M, Alagoz O, Sprague BL, Tosteson AN, Miglioretti DL, Kerlikowske K, Stout NK, Jarvik JG, Ramsey SD, Lehman CD. Comparative effectiveness of combined digital mammography and tomosynthesis screening for women with dense breasts. Radiology. 2015 Mar;274(3):772-80. doi: 10.1148/radiol.14141237. Epub 2014 Oct 28.</citation>
    <PMID>25350548</PMID>
  </reference>
  <reference>
    <citation>Moger TA, Bjørnelv GM, Aas E. Expected 10-year treatment cost of breast cancer detected within and outside a public screening program in Norway. Eur J Health Econ. 2016 Jul;17(6):745-54. doi: 10.1007/s10198-015-0719-4. Epub 2015 Aug 4.</citation>
    <PMID>26239280</PMID>
  </reference>
  <reference>
    <citation>Tingberg A, Zackrisson S. Digital mammography and tomosynthesis for breast cancer diagnosis. Expert Opin Med Diagn. 2011 Nov;5(6):517-26. doi: 10.1517/17530059.2011.616492. Epub 2011 Sep 6.</citation>
    <PMID>23484749</PMID>
  </reference>
  <results_reference>
    <citation>Aase HS, Holen ÅS, Pedersen K, Houssami N, Haldorsen IS, Sebuødegård S, Hanestad B, Hofvind S. A randomized controlled trial of digital breast tomosynthesis versus digital mammography in population-based screening in Bergen: interim analysis of performance indicators from the To-Be trial. Eur Radiol. 2019 Mar;29(3):1175-1186. doi: 10.1007/s00330-018-5690-x. Epub 2018 Aug 29.</citation>
    <PMID>30159620</PMID>
  </results_reference>
  <results_reference>
    <citation>Hofvind S, Holen ÅS, Aase HS, Houssami N, Sebuødegård S, Moger TA, Haldorsen IS, Akslen LA. Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial. Lancet Oncol. 2019 Jun;20(6):795-805. doi: 10.1016/S1470-2045(19)30161-5. Epub 2019 May 8. Erratum in: Lancet Oncol. 2019 Jul;20(7):e346.</citation>
    <PMID>31078459</PMID>
  </results_reference>
  <results_reference>
    <citation>Moger TA, Swanson JO, Holen ÅS, Hanestad B, Hofvind S. Cost differences between digital tomosynthesis and standard digital mammography in a breast cancer screening programme: results from the To-Be trial in Norway. Eur J Health Econ. 2019 Nov;20(8):1261-1269. doi: 10.1007/s10198-019-01094-7. Epub 2019 Aug 9.</citation>
    <PMID>31399773</PMID>
  </results_reference>
  <results_reference>
    <citation>Waade GG, Holen Å, Sebuødegård S, Aase H, Pedersen K, Hanestad B, Hofvind S. Breast compression parameters among women screened with standard digital mammography and digital breast tomosynthesis in a randomized controlled trial. Acta Radiol. 2020 Mar;61(3):321-330. doi: 10.1177/0284185119863989. Epub 2019 Jul 25.</citation>
    <PMID>31342757</PMID>
  </results_reference>
  <results_reference>
    <citation>Moshina N, Aase HS, Danielsen AS, Haldorsen IS, Lee CI, Zackrisson S, Hofvind S. Comparing Screening Outcomes for Digital Breast Tomosynthesis and Digital Mammography by Automated Breast Density in a Randomized Controlled Trial: Results from the To-Be Trial. Radiology. 2020 Dec;297(3):522-531. doi: 10.1148/radiol.2020201150. Epub 2020 Sep 15.</citation>
    <PMID>32930649</PMID>
  </results_reference>
  <results_reference>
    <citation>Aase HS, Danielsen AS, Hoff SR, Holen ÅS, Haldorsen IS, Hovda T, Hanestad B, Sandvik CK, Hofvind S. Mammographic features and screening outcome in a randomized controlled trial comparing digital breast tomosynthesis and digital mammography. Eur J Radiol. 2021 Aug;141:109753. doi: 10.1016/j.ejrad.2021.109753. Epub 2021 May 5.</citation>
    <PMID>34053786</PMID>
  </results_reference>
  <results_reference>
    <citation>Hofvind S, Moshina N, Holen ÅS, Danielsen AS, Lee CI, Houssami N, Aase HS, Akslen LA, Haldorsen IS. Interval and Subsequent Round Breast Cancer in a Randomized Controlled Trial Comparing Digital Breast Tomosynthesis and Digital Mammography Screening. Radiology. 2021 Jul;300(1):66-76. doi: 10.1148/radiol.2021203936. Epub 2021 May 11.</citation>
    <PMID>33973840</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 23, 2016</study_first_submitted>
  <study_first_submitted_qc>July 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2016</study_first_posted>
  <results_first_submitted>March 30, 2020</results_first_submitted>
  <results_first_submitted_qc>December 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 15, 2021</results_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diagnostic Imaging</keyword>
  <keyword>Mammography</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Tomosynthesis</keyword>
  <keyword>Early performance measures</keyword>
  <keyword>Recall</keyword>
  <keyword>Radiation dose</keyword>
  <keyword>Cancer detection</keyword>
  <keyword>Sensitivity</keyword>
  <keyword>Specificity</keyword>
  <keyword>Cost</keyword>
  <keyword>Economy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We will not share the data outside the project group</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 14, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT02835625/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Women were invited to participate when attending screening at the screening unit Danmarksplass in Bergen, Norway. The recruitment period lasted from January 14th 2016 to December 15th 2017.</recruitment_details>
      <pre_assignment_details>Women that attended screening but had breast implant were not invited to participate, and thus not randomized to either of the study groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Digital Breast Tomosynthesis</title>
          <description>Digital Breast Tomosynthesis + Synthetic Mammography (DBT)&#xD;
The DBT was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.&#xD;
Women selected for further assessment (positive screening exam) was recalled.&#xD;
Digital Breast Tomosynthesis + Synthetic Mammography: Two-view tomosynthesis performed with GE SenoClaire 3D Breast Tomosynthesis.</description>
        </group>
        <group group_id="P2">
          <title>Digital Mammography</title>
          <description>The digital mammograms was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.&#xD;
Women selected for further assessment (positive screening exam) was recalled.&#xD;
Digital mammography: Two-view digital mammography performed with GE SenoClaire 3D Breast Tomosynthesis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14734"/>
                <participants group_id="P2" count="14719"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14734"/>
                <participants group_id="P2" count="14719"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>We excluded women with previous breast cancer (DBT = 314, DM = 316), women with breast symptoms at screening (DBT = 39, DM = 34) and one woman with metastasis from melanoma (DBT).</population>
      <group_list>
        <group group_id="B1">
          <title>Digital Breast Tomosynthesis</title>
          <description>Digital Breast Tomosynthesis + Synthetic Mammography (DBT)&#xD;
The DBT was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.&#xD;
Women selected for further assessment (positive screening exam) was recalled.&#xD;
Digital Breast Tomosynthesis + Synthetic Mammography: Two-view tomosynthesis performed with GE SenoClaire 3D Breast Tomosynthesis.</description>
        </group>
        <group group_id="B2">
          <title>Digital Mammography</title>
          <description>The digital mammograms was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.&#xD;
Women selected for further assessment (positive screening exam) was recalled.&#xD;
Digital mammography: Two-view digital mammography performed with GE SenoClaire 3D Breast Tomosynthesis.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14380"/>
            <count group_id="B2" value="14369"/>
            <count group_id="B3" value="28749"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;55 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14380"/>
                    <count group_id="B2" value="14369"/>
                    <count group_id="B3" value="28749"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3746"/>
                    <measurement group_id="B2" value="3813"/>
                    <measurement group_id="B3" value="7559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>55-59 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14380"/>
                    <count group_id="B2" value="14369"/>
                    <count group_id="B3" value="28749"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3628"/>
                    <measurement group_id="B2" value="3668"/>
                    <measurement group_id="B3" value="7296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-64 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14380"/>
                    <count group_id="B2" value="14369"/>
                    <count group_id="B3" value="28749"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3625"/>
                    <measurement group_id="B2" value="3492"/>
                    <measurement group_id="B3" value="7117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;64 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14380"/>
                    <count group_id="B2" value="14369"/>
                    <count group_id="B3" value="28749"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3381"/>
                    <measurement group_id="B2" value="3396"/>
                    <measurement group_id="B3" value="6777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14380"/>
                    <count group_id="B2" value="14369"/>
                    <count group_id="B3" value="28749"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14380"/>
                    <measurement group_id="B2" value="14369"/>
                    <measurement group_id="B3" value="28749"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Norway</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14380"/>
                    <count group_id="B2" value="14369"/>
                    <count group_id="B3" value="28749"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14380"/>
                    <measurement group_id="B2" value="14369"/>
                    <measurement group_id="B3" value="28749"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Screening history</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Prevalent (first screening)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14380"/>
                    <count group_id="B2" value="14369"/>
                    <count group_id="B3" value="28749"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2013"/>
                    <measurement group_id="B2" value="2053"/>
                    <measurement group_id="B3" value="4066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subsequent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14380"/>
                    <count group_id="B2" value="14369"/>
                    <count group_id="B3" value="28749"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12367"/>
                    <measurement group_id="B2" value="12316"/>
                    <measurement group_id="B3" value="24683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Screen-Detected Breast Cancer</title>
        <description>Comparison of rates of screen-detected breast cancer in tomosynthesis versus digital mammography as performed in a population based screening program.</description>
        <time_frame>36 months from start up of the trial</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Digital Breast Tomosynthesis</title>
            <description>Digital Breast Tomosynthesis + Synthetic Mammography (DBT)&#xD;
The DBT was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.&#xD;
Women selected for further assessment (positive screening exam) was recalled.&#xD;
Digital Breast Tomosynthesis + Synthetic Mammography: Two-view tomosynthesis performed with GE SenoClaire 3D Breast Tomosynthesis.</description>
          </group>
          <group group_id="O2">
            <title>Digital Mammography</title>
            <description>The digital mammograms was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.&#xD;
Women selected for further assessment (positive screening exam) was recalled.&#xD;
Digital mammography: Two-view digital mammography performed with GE SenoClaire 3D Breast Tomosynthesis.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Screen-Detected Breast Cancer</title>
          <description>Comparison of rates of screen-detected breast cancer in tomosynthesis versus digital mammography as performed in a population based screening program.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14380"/>
                <count group_id="O2" value="14369"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Participants Screen-Detected Breast Cancer Among Participants Recalled for Further Assesment</title>
        <description>Positive predictive value of recalls (number of screen-detected breast cancer among participants recalled for further assesment) for tomosynthesis versus digital mammography in a population based screening program.</description>
        <time_frame>36 months from start up of the trial</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Digital Breast Tomosynthesis</title>
            <description>Digital Breast Tomosynthesis + Synthetic Mammography (DBT)&#xD;
The DBT was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.&#xD;
Women selected for further assessment (positive screening exam) was recalled.&#xD;
Digital Breast Tomosynthesis + Synthetic Mammography: Two-view tomosynthesis performed with GE SenoClaire 3D Breast Tomosynthesis.</description>
          </group>
          <group group_id="O2">
            <title>Digital Mammography</title>
            <description>The digital mammograms was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.&#xD;
Women selected for further assessment (positive screening exam) was recalled.&#xD;
Digital mammography: Two-view digital mammography performed with GE SenoClaire 3D Breast Tomosynthesis.</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Participants Screen-Detected Breast Cancer Among Participants Recalled for Further Assesment</title>
          <description>Positive predictive value of recalls (number of screen-detected breast cancer among participants recalled for further assesment) for tomosynthesis versus digital mammography in a population based screening program.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="444"/>
                <count group_id="O2" value="571"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Recalled for Further Assesment Due to Mammographic Findings</title>
        <description>Comparison of rate of recall for further assesment due to mammographic findings in tomosynthesis versus digital mammography as performed in a population based screening program.</description>
        <time_frame>36 months from start up of the trial</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Digital Breast Tomosynthesis</title>
            <description>Digital Breast Tomosynthesis + Synthetic Mammography (DBT)&#xD;
The DBT was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.&#xD;
Women selected for further assessment (positive screening exam) was recalled.&#xD;
Digital Breast Tomosynthesis + Synthetic Mammography: Two-view tomosynthesis performed with GE SenoClaire 3D Breast Tomosynthesis.</description>
          </group>
          <group group_id="O2">
            <title>Digital Mammography</title>
            <description>The digital mammograms was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.&#xD;
Women selected for further assessment (positive screening exam) was recalled.&#xD;
Digital mammography: Two-view digital mammography performed with GE SenoClaire 3D Breast Tomosynthesis.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Recalled for Further Assesment Due to Mammographic Findings</title>
          <description>Comparison of rate of recall for further assesment due to mammographic findings in tomosynthesis versus digital mammography as performed in a population based screening program.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14380"/>
                <count group_id="O2" value="14369"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="444"/>
                    <measurement group_id="O2" value="571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incremental Costs of Screening With Tomosynthesis Versus Digital Mammography</title>
        <description>The incremental cost per woman screened with digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening program.</description>
        <time_frame>36 months from start up of the trial</time_frame>
        <population>For each participant, the incremental cost of tomosynthesis vs. digital mammography were estimated, not the total cost of tomosynthesis vs. digital mammography. The investigators assumed that costs not pertaining to examination and reading times, mammograph price, IT storage and connectivity were equal for the two. This Outcome Measure was pre-specified to present the incremental costs per screened woman. By nature, incremental costs are calculated between groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Digital Breast Tomosynthesis Versus Digital Mammography</title>
            <description>Comparing costs of procedure use and screening, recall and treatment costs estimated at the individual level for Digital Breast Tomosynthesis + Synthetic Mammography (DBT) versus Digital Mammography (DM).</description>
          </group>
        </group_list>
        <measure>
          <title>Incremental Costs of Screening With Tomosynthesis Versus Digital Mammography</title>
          <description>The incremental cost per woman screened with digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening program.</description>
          <population>For each participant, the incremental cost of tomosynthesis vs. digital mammography were estimated, not the total cost of tomosynthesis vs. digital mammography. The investigators assumed that costs not pertaining to examination and reading times, mammograph price, IT storage and connectivity were equal for the two. This Outcome Measure was pre-specified to present the incremental costs per screened woman. By nature, incremental costs are calculated between groups.</population>
          <units>€</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29453"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Incremental costs of DBT vs. DM in Euro</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="8.4" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incremental cost of DBT vs. DM after adding costs of recall, in Euro</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" lower_limit="4.6" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prognostic and Predictive Tumor Characteristics for Screen-Detected Breast Cancer</title>
        <description>Distribution of characteristics among the women diagnosed with breast cancer screened with tomosynthesis versus digital mammography in a population based screening program.</description>
        <time_frame>36 months from start up of the trial</time_frame>
        <population>When collecting information on histopathological tumor characteristics, not all participants had information available on all variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Digital Breast Tomosynthesis</title>
            <description>Digital Breast Tomosynthesis + Synthetic Mammography (DBT)&#xD;
The DBT was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.&#xD;
Women selected for further assessment (positive screening exam) was recalled.&#xD;
Digital Breast Tomosynthesis + Synthetic Mammography: Two-view tomosynthesis performed with GE SenoClaire 3D Breast Tomosynthesis.</description>
          </group>
          <group group_id="O2">
            <title>Digital Mammography</title>
            <description>The digital mammograms was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.&#xD;
Women selected for further assessment (positive screening exam) was recalled.&#xD;
Digital mammography: Two-view digital mammography performed with GE SenoClaire 3D Breast Tomosynthesis.</description>
          </group>
        </group_list>
        <measure>
          <title>Prognostic and Predictive Tumor Characteristics for Screen-Detected Breast Cancer</title>
          <description>Distribution of characteristics among the women diagnosed with breast cancer screened with tomosynthesis versus digital mammography in a population based screening program.</description>
          <population>When collecting information on histopathological tumor characteristics, not all participants had information available on all variables.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Histological type : Carcinoma (no special type)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Histological type : Lobular carcinoma</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Histological type : Tubular carcinoma</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Histological type : Other carcinoma</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor diameter : &lt;10 mm</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor diameter : &gt;=10-&lt;20 mm</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor diameter : &gt;=20 mm</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph node positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Histological grade : grade 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Histological grade : grade 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Histological grade : grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estrogen receptor positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progesterone receptor positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HER2 positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ki67 &gt;=30%</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Interval Breast Cancer</title>
        <description>Rate of interval breast cancer among those screened with tomosynthesis versus digital mammography as performed in a population based screening program.</description>
        <time_frame>60 months from start up of the trial</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Digital Breast Tomosynthesis</title>
            <description>Digital Breast Tomosynthesis + Synthetic Mammography (DBT)&#xD;
The DBT was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.&#xD;
Women selected for further assessment (positive screening exam) was recalled.&#xD;
Digital Breast Tomosynthesis + Synthetic Mammography: Two-view tomosynthesis performed with GE SenoClaire 3D Breast Tomosynthesis.</description>
          </group>
          <group group_id="O2">
            <title>Digital Mammography</title>
            <description>The digital mammograms was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.&#xD;
Women selected for further assessment (positive screening exam) was recalled.&#xD;
Digital mammography: Two-view digital mammography performed with GE SenoClaire 3D Breast Tomosynthesis.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Interval Breast Cancer</title>
          <description>Rate of interval breast cancer among those screened with tomosynthesis versus digital mammography as performed in a population based screening program.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14380"/>
                <count group_id="O2" value="14369"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time Spent on Screen-Reading and Consensus Meetings</title>
        <description>The time spent on screen-reading and consensus will be compared for tomosynthesis versus digital mammography</description>
        <time_frame>24 months from start up of the trial</time_frame>
        <population>Interim analysis performed on study population from the first year of the trial (2016). All cases were screen-read by two radiologist, however not all were discussed at consensus.</population>
        <group_list>
          <group group_id="O1">
            <title>Digital Breast Tomosynthesis</title>
            <description>Digital Breast Tomosynthesis + Synthetic Mammography (DBT)&#xD;
The DBT was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.&#xD;
Women selected for further assessment (positive screening exam) was recalled.&#xD;
Digital Breast Tomosynthesis + Synthetic Mammography: Two-view tomosynthesis performed with GE SenoClaire 3D Breast Tomosynthesis.</description>
          </group>
          <group group_id="O2">
            <title>Digital Mammography</title>
            <description>The digital mammograms was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.&#xD;
Women selected for further assessment (positive screening exam) was recalled.&#xD;
Digital mammography: Two-view digital mammography performed with GE SenoClaire 3D Breast Tomosynthesis.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent on Screen-Reading and Consensus Meetings</title>
          <description>The time spent on screen-reading and consensus will be compared for tomosynthesis versus digital mammography</description>
          <population>Interim analysis performed on study population from the first year of the trial (2016). All cases were screen-read by two radiologist, however not all were discussed at consensus.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7037"/>
                <count group_id="O2" value="7052"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Initial screen reading</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7037"/>
                    <count group_id="O2" value="7052"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5" spread="54.4"/>
                    <measurement group_id="O2" value="41.3" spread="49.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Consensus reading</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="447"/>
                    <count group_id="O2" value="513"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192.1" spread="118.1"/>
                    <measurement group_id="O2" value="131.9" spread="79.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mammographic Features of Screen-Detected Breast Cancer</title>
        <description>Distribution of characteristics among the women diagnosed with breast cancer screened with tomosynthesis versus digital mammography in a population based screening program.</description>
        <time_frame>36 months from start up of the trial</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Digital Breast Tomosynthesis</title>
            <description>Digital Breast Tomosynthesis + Synthetic Mammography (DBT)&#xD;
The DBT was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.&#xD;
Women selected for further assessment (positive screening exam) was recalled.&#xD;
Digital Breast Tomosynthesis + Synthetic Mammography: Two-view tomosynthesis performed with GE SenoClaire 3D Breast Tomosynthesis.</description>
          </group>
          <group group_id="O2">
            <title>Digital Mammography</title>
            <description>The digital mammograms was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.&#xD;
Women selected for further assessment (positive screening exam) was recalled.&#xD;
Digital mammography: Two-view digital mammography performed with GE SenoClaire 3D Breast Tomosynthesis.</description>
          </group>
        </group_list>
        <measure>
          <title>Mammographic Features of Screen-Detected Breast Cancer</title>
          <description>Distribution of characteristics among the women diagnosed with breast cancer screened with tomosynthesis versus digital mammography in a population based screening program.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Spiculated mass</title>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Indistinct mass</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Calcifications</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Architectural distortion</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asymmetry</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mass with calcifications</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Circumscribed mass</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Obscured mass</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Associated features</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Radiation Doses When Screening With Tomosynthesis Versus Digital Mammography</title>
        <description>Radiation doses will be measured for screening with tomosynthesis and digital mammography by an automated software, in milligray (mGy).</description>
        <time_frame>24 months from start up of the trial</time_frame>
        <population>Interim analysis performed on study population from the first year of the trial (2016). Not all women had available information on radiation dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Digital Breast Tomosynthesis</title>
            <description>Digital Breast Tomosynthesis + Synthetic Mammography (DBT)&#xD;
The DBT was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.&#xD;
Women selected for further assessment (positive screening exam) was recalled.&#xD;
Digital Breast Tomosynthesis + Synthetic Mammography: Two-view tomosynthesis performed with GE SenoClaire 3D Breast Tomosynthesis.</description>
          </group>
          <group group_id="O2">
            <title>Digital Mammography</title>
            <description>The digital mammograms was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.&#xD;
Women selected for further assessment (positive screening exam) was recalled.&#xD;
Digital mammography: Two-view digital mammography performed with GE SenoClaire 3D Breast Tomosynthesis.</description>
          </group>
        </group_list>
        <measure>
          <title>Radiation Doses When Screening With Tomosynthesis Versus Digital Mammography</title>
          <description>Radiation doses will be measured for screening with tomosynthesis and digital mammography by an automated software, in milligray (mGy).</description>
          <population>Interim analysis performed on study population from the first year of the trial (2016). Not all women had available information on radiation dose.</population>
          <units>mGy</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6957"/>
                <count group_id="O2" value="6972"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.96" spread="0.62"/>
                    <measurement group_id="O2" value="2.95" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participant were followed for two years after the recruitment period for the study ended (December 31st 2017) to collect data on adverse events. Reporting of adverse events are not yet complete as we rely on data from the Norwegian Cause of Death Registry.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Digital Breast Tomosynthesis</title>
          <description>Digital Breast Tomosynthesis + Synthetic Mammography (DBT)&#xD;
The DBT was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.&#xD;
Women selected for further assessment (positive screening exam) was recalled.&#xD;
Digital Breast Tomosynthesis + Synthetic Mammography: Two-view tomosynthesis performed with GE SenoClaire 3D Breast Tomosynthesis.</description>
        </group>
        <group group_id="E2">
          <title>Digital Mammography</title>
          <description>The digital mammograms was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.&#xD;
Women selected for further assessment (positive screening exam) was recalled.&#xD;
Digital mammography: Two-view digital mammography performed with GE SenoClaire 3D Breast Tomosynthesis.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14734"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14719"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14734"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14719"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14734"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14719"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Solveig Hofvind</name_or_title>
      <organization>Cancer Registry of Norway</organization>
      <phone>+47 22928828</phone>
      <email>solveig.hofvind@kreftregisteret.no</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

